Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Annual Meeting Materials
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • FBIOP Announcements
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

May 26, 2020

Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders

May 22, 2020

Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy

May 12, 2020

Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights

May 11, 2020

Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

May 11, 2020

Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

May 11, 2020

Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers

May 08, 2020

Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

May 06, 2020

Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters

Apr 23, 2020

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab

Apr 21, 2020
RSS
  • Prev
    • 1...
    • 40
    • 41
    • 42
    • 43
    • 44
    • 45
    • 46
    • 47
    • 48
    • 49
    • ...71
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap